var data={"title":"Rituximab (intravenous): Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Rituximab (intravenous): Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6919?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=rituximab-intravenous-drug-information\" class=\"drug drug_general\">see &quot;Rituximab (intravenous): Drug information&quot;</a> and <a href=\"topic.htm?path=rituximab-intravenous-patient-drug-information\" class=\"drug drug_patient\">see &quot;Rituximab (intravenous): Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5709404\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Infusion reactions:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Rituximab administration can result in serious, including fatal, infusion reactions. Deaths within 24 hours of rituximab infusion have been reported. Approximately 80% of fatal infusion reactions occurred in association with the first infusion.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Monitor patients closely. Discontinue rituximab infusion for severe reactions and administer medical treatment for grade 3 or 4 infusion reactions.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Mucocutaneous reactions:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Severe, including fatal, mucocutaneous reactions can occur in patients receiving rituximab.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Hepatitis B virus reactivation:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Hepatitis B virus (HBV) reactivation can occur in patients treated with rituximab, in some cases resulting in fulminant hepatitis, hepatic failure, and death. Screen all patients for HBV infection before treatment initiation, and monitor patients during and after treatment with rituximab. Discontinue rituximab and concomitant medications in the event of HBV reactivation.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Progressive multifocal leukoencephalopathy:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Progressive multifocal leukoencephalopathy (PML) and death can occur in patients receiving rituximab.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218842\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Rituxan</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218843\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Rituxan</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1049762\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antineoplastic Agent, Anti-CD20</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Antineoplastic Agent, Monoclonal Antibody</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Antirheumatic Miscellaneous</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Immunosuppressant Agent</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Monoclonal Antibody</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1049754\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=rituximab-intravenous-drug-information\" class=\"drug drug_general\">see &quot;Rituximab (intravenous): Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">Refer to individual protocols. Pretreatment with acetaminophen and an antihistamine is recommended for all indications. For oncology uses, a uricostatic agent (eg, allopurinol) and aggressive hydration is recommended for patients at risk for tumor lysis syndrome (high tumor burden or lymphocytes &gt;25,000/mm<sup>3</sup>). In patients with CLL, <i>pneumocystis jirovecii</i> pneumonia (PCP) and antiherpetic viral prophylaxis is recommended during treatment (and for up to 12 months following treatment). In patients with WG and MPA, PCP prophylaxis is recommended during and for 6 months after rituximab treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infants, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Autoimmune hemolytic anemia:</b> Infants &ge;4 months, Children, and Adolescents: IV infusion: 375 mg/m<sup>2</sup> once weekly for 2-4 doses (Zecca, 2003)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Chronic ITP:</b> Children and Adolescents: IV infusion: 375 mg/m<sup>2</sup> once weekly for 4 doses (Parodi, 2009; Wang, 2005)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Post-transplant lymphoproliferative disorder:</b> Infants &ge;11 months, Children, and Adolescents: IV infusion: 375 mg/m<sup>2</sup> once weekly for 3-4 doses (Milpied, 2000; Serinet, 2002)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Refractory SLE:</b> Children &ge;8 years and Adolescents: IV infusion: 375 mg/m<sup>2</sup> once weekly for 2-4 doses; or 750 mg/m<sup>2</sup> on days 1 and 15 (maximum dose: 1000 mg) (Marks, 2005)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Refractory severe nephrotic syndrome:</b> Infants &ge;11 months, Children, and Adolescents: IV infusion: 375 mg/m<sup>2</sup> once weekly for 1-4 doses has been used in small case series, case reports, and retrospective analyses, including reports of successful remission induction of severe or refractory nephrotic syndromes that are poorly responsive to standard therapies (Della Strologo, 2009; Fujinaga, 2010; Gugonis, 2008; Kaito, 2010; Prytula, 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>CLL:</b> IV infusion: 375 mg/m<sup>2</sup> on the day prior to fludarabine/cyclophosphamide in cycle 1, then 500 mg/m<sup>2</sup> on day 1 (every 28 days) of cycles 2-6</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Granulomatosis with polyangiitis (GPA; Wegener&rsquo;s granulomatosis) and Microscopic polyangiitis (MPA):</b> IV infusion: 375 mg/m<sup>2</sup> once weekly for 4 doses (in combination with methylprednisolone IV for 1-3 days followed by daily prednisone)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>NHL (relapsed/refractory, low-grade or follicular CD20-positive, B-cell):</b> IV infusion: 375 mg/m<sup>2</sup> once weekly for 4 or 8 doses</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Retreatment following disease progression: IV infusion: 375 mg/m<sup>2</sup> once weekly for 4 doses</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>NHL (diffuse large B-cell):</b> IV infusion: 375 mg/m<sup>2</sup> given on day 1 of each chemotherapy cycle for up to 8 doses</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>NHL (follicular, CD20-positive, B-cell, previously untreated):</b> IV infusion: 375 mg/m<sup>2</sup> given on day 1 of each chemotherapy cycle for up to 8 doses</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Maintenance therapy (as a single agent, in patients with partial or complete response to rituximab plus chemotherapy; begin 8 weeks after completion of combination chemotherapy): IV infusion: 375 mg/m<sup>2</sup> every 8 weeks for 12 doses</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>NHL (nonprogressing, low-grade, CD20-positive, B-cell, after first-line CVP)</b>: IV infusion: 375 mg/m<sup>2</sup> once weekly for 4 doses every 6 months for up to 4 cycles (initiate after 6-8 cycles of chemotherapy are completed)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>NHL:</b> Combination therapy with ibritumomab: IV infusion: 250 mg/m<sup>2</sup> IV day 1; repeat in 7-9 days with ibritumomab</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Rheumatoid arthritis:</b> IV infusion: 1000 mg on days 1 and 15 in combination with methotrexate; subsequent courses may be administered every 24 weeks (based on clinical evaluation), if necessary may be repeated no sooner than every 16 weeks. <b>Note:</b> Premedication with methylprednisolone 100 mg IV (or equivalent) is recommended 30 minutes prior to each dose.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218822\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Rituxan: 10 mg/mL (10 mL, 50 mL) [contains polysorbate 80]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218808\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7882123\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and at <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/UCM169892.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/+nIf162NgDrXSMpjxmnBPQrCpoXb/G/zezHY8vQZBZkA==&amp;TOPIC_ID=12971\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/UCM169892.pdf</a>, must be dispensed with this medication.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1049766\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">IV infusion: <b>DO NOT ADMINISTER UNDILUTED OR as an IV push or rapid injection:</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> Some pediatric protocols utilize an alternate rituximab administration rate. Refer to specific protocol for administration rate guidelines.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Initial infusion: Start at a rate of 50 mg/hour. If no hypersensitivity or infusion-related reactions occur, increase infusion rate in 50 mg/hour increments every 30 minutes to a maximum infusion rate of 400 mg/hour as tolerated. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Subsequent infusions: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Standard infusion rate: If patient tolerated initial infusion, start at 100 mg/hour and increased by 100 mg/hour increments at 30 minute intervals to a maximum infusion rate of 400 mg/hour. If hypersensitivity or infusion-related reactions occur, slow or interrupt the infusion. If symptoms completely resolve, resume infusion at 50% of the previous rate.  </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Accelerated infusion rate (90 minutes): For adult patients with previously untreated follicular NHL and diffuse large B-cell NHL who are receiving a corticosteroid as part of their combination chemotherapy regimen, have a circulating lymphocyte count &lt;5,000/mm<sup>3</sup>, or have no significant cardiovascular disease. After tolerance has been established (no grade 3 or 4 infusion-related event) at the recommended infusion rate in cycle 1, a rapid infusion rate may be used beginning with cycle 2. The daily corticosteroid, acetaminophen, and diphenhydramine are administered prior to treatment, then the rituximab dose is administered over 90 minutes, with 20% of the dose administered over the first 30 minutes and the remaining 80% is given over 60 minutes (Sehn 2007). If the 90-minute infusion in cycle 2 is tolerated, the same rate may be used for the remainder of the treatment regimen (through cycles 6 or 8).  </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218838\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store intact vials at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F); do not freeze. Do not shake. Protect vials from direct sunlight. Solutions for infusion in NS or D5W are stable at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F) for 24 hours and at room temperature for an additional 24 hours (although because there is no preservative, the manufacturer recommends storing refrigerated).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1049765\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of CD20-positive, B-cell non-Hodgkin's lymphoma (NHL) [including relapsed or refractory, low-grade or follicular B-cell NHL (as a single agent); follicular B-cell NHL, previously untreated (in combination with first-line chemotherapy, and as single-agent maintenance therapy if response to first-line rituximab with chemotherapy); nonprogressing, low-grade B-cell NHL (as a single agent after first-line CVP treatment), diffuse large B-cell NHL, previously untreated (in combination with CHOP chemotherapy or other anthracycline-based regimen)]; treatment of CD20-positive chronic lymphocytic leukemia (CLL) (in combination with cyclophosphamide and fludarabine); treatment of moderately- to severely-active rheumatoid arthritis (in combination with methotrexate) in patients with inadequate response to one or more TNF antagonists; treatment of granulomatosis with polyangiitis (GPA; Wegener&rsquo;s Granulomatosis) and microscopic polyangiitis (MPA)  in combination with glucorticoids (FDA approved in adults); has also been used for the treatment of systemic autoimmune disorders (other than rheumatoid arthritis; ie, autoimmune hemolytic anemia in children); refractory systemic lupus erythematosus; steroid-refractory chronic graft-versus-host disease (GVHD); refractory nephrotic syndrome, chronic immune thrombocytopenia (ITP); post-transplant lymphoproliferative disorder (PTLD) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218877\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Rituxan may be confused with Remicade, Rituxan Hycela</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">RiTUXimab may be confused with brentuximab, bevacizumab, inFLIXimab, obinutuzumab, ofatumumab, ramucirumab, rituximab and hyaluronidase, ruxolitinib</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes that have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Administration issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Rituximab is for intravenous (IV) administration only. Do not substitute rituximab and hyaluronidase (SubQ) for rituximab (IV). Use caution during product selection, preparation, and administration.</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">The rituximab dose for rheumatoid arthritis is a flat dose (1000 mg) and is not based on body surface area (BSA).</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218875\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Patients treated with rituximab for rheumatoid arthritis (RA) may experience fewer adverse reactions.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Flushing, hypertension, hypotension, peripheral edema</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Anxiety, chills, dizziness, fatigue, headache, insomnia, migraine (RA), neuropathy, pain, paresthesia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Night sweats, pruritus, skin rash, urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Hyperglycemia, increased lactate dehydrogenase, weight gain</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal pain, diarrhea, dyspepsia (RA), nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Anemia (less common in grades 3/4), cytopenia (may be prolonged, leukopenia, febrile neutropenia (CLL), lymphocytopenia (median duration: 14 days), neutropenia (more common in CLL: grades 3/4; median duration: 13 days; late-onset neutropenia occurs &gt;40 days after last dose), thrombocytopenia)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Increased serum ALT</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Angioedema</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Immunologic: Antibody development (human antichimeric antibody [HACA] positive)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infection: Bacterial infection, fungal infection, infection, viral infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Arthralgia, back pain, muscle spasm, myalgia, weakness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Bronchospasm, cough, dyspnea, epistaxis, rhinitis, sinusitis, throat irritation, upper respiratory tract infection (RA)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever, infusion related reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Acute mucocutaneous toxicity, acute renal failure, acute respiratory distress, anaphylactoid reaction, anaphylaxis, angina pectoris, aplastic anemia, arthritis (polyarticular), bone marrow depression, bronchiolitis obliterans, cardiac arrhythmia, cardiac failure, cardiogenic shock, encephalitis, fulminant hepatitis, gastrointestinal perforation, hemolytic anemia, hepatic failure, hepatitis, hypogammaglobulinemia (prolonged), hypoxia, increased serum immunoglobulins (hyperviscosity syndrome in Waldenstrom&rsquo;s macroglobulinemia), interstitial pneumonitis, intestinal obstruction, intestinal perforation, Kaposi&rsquo;s sarcoma (progression), laryngeal edema, lichenoid dermatitis, lupus-like syndrome,  mucositis, myelitis, myocardial infarction, nephrotoxicity, optic neuritis, pancytopenia (prolonged), pemphigus (paraneoplastic; uncommon), pleurisy, pneumonia, pneumonitis, polymyositis, progressive multifocal leukoencephalopathy, pure red cell aplasia, reactivated tuberculosis, reactivation of HBV, reversible posterior leukoencephalopathy syndrome, serum sickness, Stevens-Johnson syndrome, supraventricular cardiac arrhythmia, toxic epidermal necrolysis, tumor lysis syndrome, uveitis, vasculitic rash, vasculitis (systemic), ventricular fibrillation, ventricular tachycardia, vesiculobullous dermatitis, viral infection (reactivation; includes JC virus infection, cytomegalovirus, herpes simplex virus, parvovirus B19, varicella-zoster virus, West Nile disease, and hepatitis C), wheezing</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218829\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">There are no contraindications listed in the manufacturer's US labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Known type 1 hypersensitivity or anaphylactic reaction to murine proteins, Chinese Hamster Ovary (CHO) cell proteins, or any component of the formulation; patients who have or have had progressive multifocal leukoencephalopathy (PML); patients with severe, active infections</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218812\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bowel obstruction/perforation: Abdominal pain, bowel obstruction, and perforation have been reported (rarely fatal), with an average onset of symptoms of ~6 days (range: 1 to 77 days); evaluate abdominal pain or repeated vomiting.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular effects: Discontinue infusion for serious or life-threatening cardiac arrhythmias. Perform cardiac monitoring during and after the infusion in patients who develop clinically significant arrhythmias or who have a history of arrhythmia or angina.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cytopenias: Rituximab is associated with lymphopenia, leukopenia, neutropenia, thrombocytopenia, and anemia; the duration of cytopenias may be prolonged and may extend months beyond treatment. Monitor blood counts.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatitis B virus reactivation:<b> [US Boxed Warning]: Hepatitis B virus (HBV) reactivation may occur with rituximab and in some cases may result in fulminant hepatitis, hepatic failure, and death. Screen all patients for HBV infection prior to treatment initiation, and monitor patients during and after treatment with rituximab. Discontinue rituximab and concomitant medications in the event of HBV reactivation.</b> Screening should include hepatitis B surface antigen (HBsAg) and hepatitis B core antibody (anti-HBc); monitor patients for clinical and laboratory signs of hepatitis or HBV reactivation during and for several months after treatment. If viral hepatitis develops, initiate appropriate antiviral therapy. Reactivation has occurred in patients who are HBsAg positive as well as in those who are HBsAg negative but are anti-HBc positive; HBV reactivation has also been observed in patients who had previously resolved HBV infection. HBV reactivation has been reported up to 24 months after discontinuation. Use cautiously in patients who show evidence of prior HBV infection (eg, HBsAg positive [regardless of antibody status] or HBsAg negative but anti-HBc positive); consult with appropriate clinicians regarding monitoring and consideration of antiviral therapy before and/or during rituximab treatment. The safety of resuming rituximab treatment following HBV reactivation is not known; discuss reinitiation of therapy in patients with resolved HBV reactivation with physicians experienced in HBV management.</p>\n    <p style=\"text-indent:0em;margin-left:6em;\">- American Society of Clinical Oncology (ASCO) provisional clinical opinion update on hepatitis B virus screening recommendations (Hwang 2015): Patients receiving anti-CD20 antibodies are at high risk for hepatitis B virus (HBV) reactivation. Screen for HBV infection with HBsAg and anti-HBc tests prior to treatment initiation; either a total anti-HBc (with both IgG and IgM) or anti-HBc IgG test should be used to screen for chronic or resolved HBV infection (do not use anti-HBc IgM as it may only confirm acute HBV infection). In addition, patients who have risk factors for HBV infection (eg, birthplace in a country with &ge;2% HBV prevalence, household or sexual contact with HBV infected patients, high-risk behaviors [eg, intravenous drug use], and HIV infection) should also be screened prior to beginning therapy. Initiate prophylactic antiviral therapy (utilizing antivirals with low rates of viral resistance) for HBsAg positive/anti-HBc positive patients (without delaying cancer therapy) and continue the antivirals during and for ~6 to 12 months after completing treatment. HBsAg negative/anti-HBc positive patients should be monitored for HBV reactivation with HBV DNA and ALT testing approximately every 3 months during treatment; antiviral therapy may be initiated prophylactically or begun promptly at the first sign of HBV reactivation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Infections: Use is not recommended in patients with severe active infection. Serious and potentially fatal bacterial, fungal, and either new or reactivated viral infections may occur during treatment and after completing rituximab. Infections have been observed in patients with prolonged hypogammaglobulinemia, defined as hypogammaglobulinemia &gt;11 months after rituximab exposure. Associated new or reactivated viral infections have included cytomegalovirus, herpes simplex virus, parvovirus B19, varicella zoster virus, West Nile virus, and hepatitis B and C. Discontinue rituximab (and concomitant chemotherapy) in patients who develop viral hepatitis and initiate antiviral therapy. Discontinue rituximab in patients who develop other serious infections and initiate appropriate anti-infective treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Infusion reactions: <b>[US Boxed Warning]: Serious (including fatal) infusion-related reactions have been reported, usually with the first infusion; fatalities have been reported within 24 hours of infusion; monitor closely during infusion; discontinue for severe reactions and provide medical intervention for grades 3 or 4 infusion reactions.</b> Reactions usually occur within 30 to 120 minutes and may include hypotension, angioedema, bronchospasm, hypoxia, urticaria, and in more severe cases pulmonary infiltrates, acute respiratory distress syndrome, myocardial infarction, ventricular fibrillation, cardiogenic shock, and/or anaphylactoid events. Closely monitor patients with a history of prior cardiopulmonary reactions or with preexisting cardiac or pulmonary conditions and patients with high numbers of circulating malignant cells (&gt;25,000/mm<sup>3</sup>). Prior to infusion, premedicate patients with acetaminophen and an antihistamine (and methylprednisolone for patients with RA). Medications for the treatment of hypersensitivity reactions (eg, bronchodilators, epinephrine, corticosteroids, oxygen) should be available for immediate use; treatment is symptomatic. If infusion reaction occurs, temporarily or permanently discontinue infusion (depending on the severity of the reaction and required interventions). After symptoms resolve, infusion may be resumed with at least a 50% infusion rate reduction.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Mucocutaneous reactions: <b>[US Boxed Warning]: Severe and sometimes fatal mucocutaneous reactions (lichenoid dermatitis, paraneoplastic pemphigus, Stevens-Johnson syndrome, toxic epidermal necrolysis and vesiculobullous dermatitis) have been reported;</b> onset has been variable but has occurred as early as the first day of exposure. Discontinue in patients experiencing severe mucocutaneous skin reactions; the safety of reexposure following mucocutaneous reactions has not been evaluated.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Progressive multifocal leukoencephalopathy: <b>[US Boxed Warning]: Progressive multifocal leukoencephalopathy (PML) due to JC virus infection has been reported with rituximab; may be fatal.</b> Cases were reported in patients with hematologic malignancies receiving rituximab either with combination chemotherapy, or with hematopoietic stem cell transplant. Cases were also reported in patients receiving rituximab for autoimmune diseases who had received concurrent or prior immunosuppressant therapy. Onset may be delayed, although most cases were diagnosed within 12 months of the last rituximab dose. A retrospective analysis of patients (n=57) diagnosed with PML following rituximab therapy, found a median of 16 months (following rituximab initiation), 5.5 months (following last rituximab dose), and 6 rituximab doses preceded PML diagnosis. Clinical findings included confusion/disorientation, motor weakness/hemiparesis, altered vision/speech, and poor motor coordination with symptoms progressing over weeks to months (Carson 2009). Promptly evaluate any patient presenting with neurological changes; consider neurology consultation, brain MRI and lumbar puncture for suspected PML. Discontinue rituximab in patients who develop PML; consider reduction/discontinuation of concurrent chemotherapy or immunosuppressants.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal toxicity: May cause fatal renal toxicity in patients with NHL. Patients who received combination therapy with cisplatin and rituximab for NHL experienced renal toxicity during clinical trials; this combination is not an approved treatment regimen. Renal toxicity also occurred due to tumor lysis syndrome. Monitor for signs of renal failure; discontinue rituximab with increasing serum creatinine or oliguria.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Tumor lysis syndrome: Tumor lysis syndrome leading to acute renal failure requiring dialysis (some fatal) may occur within 12 to 24 hours following the first dose when used as a single agent in the treatment of NHL. Hyperkalemia, hypocalcemia, hyperuricemia, and/or hyperphosphatemia may occur. Administer prophylaxis (antihyperuricemic therapy, aggressive hydration) in patients at high risk (high numbers of circulating malignant cells &ge;25,000/mm<sup>3</sup> or high tumor burden). Correct electrolyte abnormalities; monitor renal function and hydration status, and administer supportive care as indicated.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Immunizations: Live vaccines should not be given concurrently with rituximab; there is no data available concerning secondary transmission of live vaccines with or following rituximab treatment. Rheumatoid arthritis patients should be brought up to date with nonlive immunizations (following current guidelines) at least 4 weeks before initiating therapy; response to some immunizations may be lower in some patients receiving rituximab.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Use with caution in the elderly. There is a higher risk of cardiac (supraventricular arrhythmia) and pulmonary adverse events (pneumonia, pneumonitis) and the incidence of serious infections and/or grade 3 or 4 adverse reactions are higher in elderly patients.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Granulomatosis with polyangiitis (GPA; Wegener granulomatosis)/microscopic polyangiitis (MPA): The safety of concomitant immunosuppressants other than corticosteroids has not been evaluated in patients with GPA or MPA after rituximab-induced B-cell depletion. There are only limited data on subsequent courses of rituximab for GPA or MPA; safety and efficacy of re-treatment have not been established.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Rheumatoid arthritis: There are limited data on the safety of other biologics or disease-modifying antirheumatic drugs (DMARDs) other than methotrexate in patients with rheumatoid arthritis with B-cell depletion following rituximab treatment. Monitor patients closely for infection if biologic agents or DMARDS are used concomitantly. The use of rituximab is not recommended in RA patients who have not had prior inadequate response to one or more TNF antagonists.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Administration: Rituximab is for IV administration only. Do not substitute rituximab and hyaluronidase (SubQ) for rituximab (IV). Use caution during product selection, preparation, and administration.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F48824494\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Neutropenia occurs in children; an open-label cohort study of 55 children with JIA treated with rituximab reported an incidence of 31% (n=17) for neutropenia; of those 17 patients with neutropenia, 16% had an ANC &lt;1,500/mm<sup>3</sup>, 9% had an ANC &lt;1,000/mm<sup>3</sup> and in 6% the ANC was &lt;500/mm<sup>3</sup>; neutropenic patients received concomitant GM-CSF (Alexeeva 2011)</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Reactivation of TB has been reported in pediatric patients receiving biologic response modifiers (infliximab and etanercept); prior to therapy, patients with no TB risk factors should be screened for latent TB infection (LTBI) with an age appropriate test (ie, &lt;5 years of age: tuberculin skin test, and &ge;5 years of age: IGRA [interferon gamma release assay]); if any TB risk factors are present or symptoms, both LTBI screening tests should be performed (AAP [Davies 2016])</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13300009\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2197621\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12971&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Abatacept: RiTUXimab may enhance the adverse/toxic effect of Abatacept. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Immunosuppressants may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Belimumab: Monoclonal Antibodies may enhance the adverse/toxic effect of Belimumab. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Certolizumab Pegol: RiTUXimab may enhance the immunosuppressive effect of Certolizumab Pegol. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Coccidioides immitis Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioides immitis Skin Test. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Echinacea: May diminish the therapeutic effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: Immunosuppressants may enhance the immunosuppressive effect of Fingolimod.  Management: Avoid the concomitant use of fingolimod and other immunosuppressants when possible. If combined, monitor patients closely for additive immunosuppressant effects (eg, infections).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nivolumab: Immunosuppressants may diminish the therapeutic effect of Nivolumab. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ocrelizumab: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pidotimod: Immunosuppressants may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tertomotide: Immunosuppressants may diminish the therapeutic effect of Tertomotide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: RiTUXimab may enhance the adverse/toxic effect of Tofacitinib. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).  Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218818\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218831\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have demonstrated adverse effects including decreased (reversible) B-cells and immunosuppression. Rituximab crosses the placenta and can be detected in the newborn. In one infant born at 41 weeks' gestation, in utero exposure occurred from week 16 to 37; rituximab concentrations were higher in the neonate at birth (32,095 ng/mL) than the mother (9,750 ng/mL) and still measurable at 18 weeks of age (700 ng/mL infant; 500 ng/mL mother) (Friedrichs 2006).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">B-cell lymphocytopenia lasting &lt;6 months may occur in exposed infants. Retrospective case reports of inadvertent pregnancy during rituximab treatment collected by the manufacturer (often combined with concomitant teratogenic therapies) describe premature births and infant hematologic abnormalities and infections; no specific pattern of birth defects has been observed (limited data) (Chakravarty 2010).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Effective contraception should be used in women of reproductive potential during and for 12 months following treatment with rituximab.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The European Society for Medical Oncology has published guidelines for diagnosis, treatment, and follow-up of cancer during pregnancy. The guidelines recommend referral to a facility with expertise in cancer during pregnancy and encourage a multidisciplinary team (obstetrician, neonatologist, oncology team). Based on limited data, if pregnancy occurs during rituximab treatment, the pregnancy may continue provided rituximab treatment is withheld. In general, although the risk of B-cell depletion in the newborn is increased, if postponing rituximab treatment would significantly compromise maternal outcome in patients diagnosed with B-cell lymphoma during pregnancy, rituximab use is not discouraged during the pregnancy (Peccatori 2013). An international consensus panel has published guidelines for hematologic malignancies during pregnancy. In patients with aggressive lymphomas, rituximab (as a component of the R-CHOP chemotherapy regimen) may be administered in the second and third trimesters, however, the cytotoxic portion of the regimen should not be administered within 3 weeks prior to anticipated delivery (Lishner 2016).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Other agents are preferred for treating lupus nephritis in pregnant women (Hahn 2012). When treating rheumatoid arthritis, it is recommended to discontinue use and switch to a safer medication prior to conception unless no other pregnancy compatible medication is able to control maternal disease (G&ouml;testam Skorpen 2016).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Data collection to monitor pregnancy and infant outcomes following exposure to rituximab is ongoing. A pregnancy registry is available for all cancers diagnosed during pregnancy at Cooper Health (877-635-4499).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1049761\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Vital signs, CBC with differential and platelet counts (obtain at weekly to monthly intervals and more frequently in patients with cytopenias, or at 2-4 month intervals in rheumatoid arthritis patients, WG and MPA), serum electrolytes, uric acid, renal function tests, liver function tests, fluid balance; monitor for infusion reactions, cardiac monitoring for patients with pre-existing cardiac condition; peripheral CD20<sup>+</sup> cells; human antimurine antibody and human antichimeric antibody titers (high levels may increase the risk of allergic reactions); screening for hepatitis B, signs or symptoms of PML, signs or symptoms of bowel obstruction/perforation  </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218811\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Rituximab is a monoclonal antibody directed against the CD20 antigen on the surface of  B-lymphocytes. CD20 regulates cell cycle initiation; and, possibly, functions as a calcium channel. Rituximab binds to the antigen on the cell surface, activating complement-dependent B-cell cytotoxicity; and to human Fc receptors, mediating cell killing through an antibody-dependent cellular toxicity. B-cells are believed to play a role in the development and progression of rheumatoid arthritis. Signs and symptoms of RA are reduced by targeting B-cells and the progression of structural damage is delayed. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218828\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immune thrombocytopenia: Initial response: 7 to 56 days; Peak response: 14 to 180 days (Neunert 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">NHL: B-cell depletion: Within 3 weeks.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Rheumatoid arthritis (RA): B-cell depletion: Within 2 weeks.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">NHL: Detectable in serum 3 to 6 months after completion of treatment; B-cell depletion is sustained for up to 6 to 9 months and B-cell recovery begins ~6 months following completion of treatment; median B-cell levels return to normal by 12 months following completion of treatment</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">RA: B-cell depletion persists for at least 6 months.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: RA: 3.1 L; GPA/MPA: 4.5 L</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CLL: Median terminal half-life: 32 days (range: 14 to 62 days)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">NHL: Median terminal half-life: 22 days (range: 6 to 52 days)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">RA: Mean terminal half-life: 18 days (range: 5 to 78 days)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">GPA/MPA: 23 days (range: 9 to 49 days)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6133643\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Rituxan Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg/10 mL (10 mL): $1,084.06</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mg/50 mL (50 mL): $5,420.28</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F218833\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Blitzima (CZ);</li>\n      <li>Mabtera (UA);</li>\n      <li>Mabthera (AE, AR, AT, AU, BB, BE, BF, BG, BH, BJ, BM, BR, BS, BZ, CH, CI, CL, CN, CO, CR, CU, CY, CZ, DE, DK, DO, EC, EE, EG, ES, ET, FI, FR, GB, GH, GM, GN, GR, GT, GY, HK, HN, HR, HU, IE, IL, IS, IT, JM, JO, KE, KR, KW, LB, LK, LR, LT, LU, LV, MA, ML, MR, MT, MU, MW, MX, MY, NE, NG, NI, NL, NO, NZ, PA, PE, PH, PK, PL, PT, PY, QA, RO, RU, SA, SC, SD, SE, SG, SI, SK, SL, SN, SR, SV, TH, TN, TR, TT, TW, TZ, UG, UY, VE, VN, ZA, ZM, ZW);</li>\n      <li>Mabthera SC (HK, MY, TH);</li>\n      <li>Reditux (IN, LK, VN);</li>\n      <li>Relito (BD);</li>\n      <li>Rituxan (JP);</li>\n      <li>Rituxim (BD)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Alade SL, Brown RE, Paquet A. Polysorbate 80 and E-Ferol toxicity. Pediatrics. 1986;77(4):593-597.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rituximab-intravenous-pediatric-drug-information/abstract-text/3960626/pubmed\" target=\"_blank\" id=\"3960626\">3960626</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Alexeeva EI, Valieva SI, Bzarova TM, et al. Efficacy and safety of repeat courses of rituximab treatment in patients with severe refractory juvenile idiopathic arthritis. <i>Clin Rheumatol</i>. 2011;30(9):1163-1172.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rituximab-intravenous-pediatric-drug-information/abstract-text/21384257/pubmed\" target=\"_blank\" id=\"21384257\">21384257</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. MMWR Morb Mortal Wkly Rep. 1984;33(14):198-199 <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rituximab-intravenous-pediatric-drug-information/abstract-text/6423951/pubmed\" target=\"_blank\" id=\"6423951\">6423951</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chakravarty EF, Murray ER, Kelman A, et al, &quot;Pregnancy Outcomes After Maternal Exposure to Rituximab,&quot; <i>Blood</i>, 2011, 117(5):1499-506.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rituximab-intravenous-pediatric-drug-information/abstract-text/21098742/pubmed\" target=\"_blank\" id=\"21098742\">21098742</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Davies HD, Committee on Infectious Disease. Infectious complications with the use of biologic response modifiers in infants and children. <i>Pediatrics</i>. 2016;138(2):e20161209.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rituximab-intravenous-pediatric-drug-information/abstract-text/27432853/pubmed\" target=\"_blank\" id=\"27432853\">27432853</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dello Strologo L, Guzzo I, Laurenzi C, et al, &quot;Use of Rituximab in Focal Glomerulosclerosis Relapses After Renal Transplantation,&quot; <i>Transplantation</i>, 2009, 88(3):417-20.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rituximab-intravenous-pediatric-drug-information/abstract-text/19667947/pubmed\" target=\"_blank\" id=\"19667947\">19667947</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Edwards JC, Szczepanski L, Szechinski J, et al, &quot;Efficacy of B-Cell-Targeted Therapy With Rituximab in Patients With Rheumatoid Arthritis,&quot; <i>N Engl J Med</i>, 2004, 350(25):2572-81.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rituximab-intravenous-pediatric-drug-information/abstract-text/15201414/pubmed\" target=\"_blank\" id=\"15201414\">15201414</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Friedrichs B, Tiemann M, Salwender H, et al. The effects of rituximab treatment during pregnancy on a neonate. <i>Haematologica</i>. 2006;91(10):1426-1427.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rituximab-intravenous-pediatric-drug-information/abstract-text/16963391/pubmed\" target=\"_blank\" id=\"16963391\">16963391</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fujinaga S, Hirano D, Nishizaki N, et al, &quot;Single Infusion of Rituximab for Persistent Steroid-Dependent Minimal-Change Nephrotic Syndrome After Long-Term Cyclosporine,&quot; <i>Pediatr Nephrol</i>, 2010, 25(3):539-44.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rituximab-intravenous-pediatric-drug-information/abstract-text/20049616/pubmed\" target=\"_blank\" id=\"20049616\">20049616</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Guigonis V, Dallocchio A, Baudouin V, et al, &quot;Rituximab Treatment for Severe Steroid- or Cyclosporine-Dependent Nephrotic Syndrome: A Multicentric Series of 22 Cases,&quot;<i> Pediatr Nephrol</i>, 2008, 23(8):1269-79.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rituximab-intravenous-pediatric-drug-information/abstract-text/18465150/pubmed\" target=\"_blank\" id=\"18465150\">18465150</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hahn BH, McMahon MA, Wilkinson A, et al, &quot;American College of Rheumatology Guidelines for Screening, Treatment, and Management of Lupus Nephritis,&quot; <i>Arthritis Care Res (Hoboken)</i>, 2012, 64(6):797-808.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rituximab-intravenous-pediatric-drug-information/abstract-text/22556106/pubmed\" target=\"_blank\" id=\"22556106\">22556106</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. Contact Dermatitis. 2002;47:313.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kaito H, Kamei K, Kikuchi E, et al, &quot;Successful Treatment of Collapsing Focal Segmental Glomerulosclerosis With a Combination of Rituximab, Steroids and Ciclosporin,&quot; <i>Pediatr Nephrol</i>, 2010, 25(5):957-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rituximab-intravenous-pediatric-drug-information/abstract-text/20033219/pubmed\" target=\"_blank\" id=\"20033219\">20033219</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. Contact Dermatitis. 2000;43:172.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Makol A, Wright K, Amin S. Rheumatoid arthritis and pregnancy: safety considerations in pharmacological management.<i> Drugs</i>. 2011;71(15):1973-1987.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rituximab-intravenous-pediatric-drug-information/abstract-text/21985166/pubmed\" target=\"_blank\" id=\"21985166\">21985166</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Marks SD, Patey S, Brogan PA, et al, &quot;B Lymphocyte Depletion Therapy in Children With Refractory Systemic Lupus Erythematosus,&quot; <i>Arthritis Rheum</i>, 2005, 52(10):3168-74.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rituximab-intravenous-pediatric-drug-information/abstract-text/16200620/pubmed\" target=\"_blank\" id=\"16200620\">16200620</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Milpied N, Vasseur B, Parquet N, et al, &quot;Humanized Anti-CD20 Monoclonal Antibody (Rituximab) in Post Transplant B-lymphoproliferative Disorder: A Retrospective Analysis on 32 Patients,&quot; <i>Ann Oncol</i>, 2000, 11 Suppl 1:113-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rituximab-intravenous-pediatric-drug-information/abstract-text/10707791/pubmed\" target=\"_blank\" id=\"10707791\">10707791</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &Oslash;stensen M, Lockshin M, Doria A, et al. Update on safety during pregnancy of biological agents and some immunosuppressive anti-rheumatic drugs. <i>Rheumatology (Oxford)</i>. 2008;47 Suppl  3:28-31.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rituximab-intravenous-pediatric-drug-information/abstract-text/18504282/pubmed\" target=\"_blank\" id=\"18504282\">18504282</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Parodi E, Rivetti E, Amendola G, et al, &quot;Long-Term Follow-Up Analysis After Rituximab Therapy in Children With Refractory Symptomatic ITP: Identification of Factors Predictive of a Sustained Response,&quot; <i>Br J Haematol</i>, 2009, 144(4):552-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rituximab-intravenous-pediatric-drug-information/abstract-text/19036077/pubmed\" target=\"_blank\" id=\"19036077\">19036077</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Provan D, Stasi R, Newland AC, et al, &quot;International Consensus Report on the Investigation and Management of Primary Immune Thrombocytopenia,&quot; <i>Blood</i>, 2010, 115(2):168-86.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rituximab-intravenous-pediatric-drug-information/abstract-text/19846889/pubmed\" target=\"_blank\" id=\"19846889\">19846889</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Prytu&#322;a A, Iijima K, Kamei K, et al, &quot;Rituximab in Refractory Nephrotic Syndrome,&quot;<i> Pediatr Nephrol</i>, 2010, 25(3):461-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rituximab-intravenous-pediatric-drug-information/abstract-text/20033225/pubmed\" target=\"_blank\" id=\"20033225\">20033225</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Serinet MO, Jacquenin E, Habes D, et al, &ldquo;Anti-CD20 Monoclonal Antibody (Rituximab) Treatment for Epstein-Barr Virus-Associated, B-Cell Lymphoproliferative Disease in Pediatric Liver Transplant Recipients,&rdquo; <i>J Ped Gastroenterology &amp; Nutrition</i>, 2002, 34(4):389-93.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rituximab-intravenous-pediatric-drug-information/abstract-text/11930095/pubmed\" target=\"_blank\" id=\"11930095\">11930095</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. Lancet. 1995;345(8980):1312-1313.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ton E, Tekstra J, Hellmann PM, et al. Safety of rituximab therapy during twins' pregnancy. <i>Rheumatology (Oxford)</i>. 2011;50(4):806-808.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rituximab-intravenous-pediatric-drug-information/abstract-text/21177333/pubmed\" target=\"_blank\" id=\"21177333\">21177333</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wang J, Wiley JM, Luddy R, et al, &quot;Chronic Immune Thrombocytopenic Purpura in Children: Assessment of Rituximab Treatment,&quot; <i>J Pediatr</i>, 2005, 146(2):217-21.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rituximab-intravenous-pediatric-drug-information/abstract-text/15689912/pubmed\" target=\"_blank\" id=\"15689912\">15689912</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zecca M, Nobili B, Ramenghi U, et al, &ldquo;Rituximab for the Treatment of Refractory Autoimmune Hemolytic Anemia in Children,&rdquo; <i>Blood</i>, 2003, 101(10):3857-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/rituximab-intravenous-pediatric-drug-information/abstract-text/12531800/pubmed\" target=\"_blank\" id=\"12531800\">12531800</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12971 Version 129.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5709404\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F218842\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F218843\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1049762\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1049754\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F218822\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F218808\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F7882123\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1049766\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F218838\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1049765\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F218877\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F218875\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F218829\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F218812\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F48824494\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13300009\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F2197621\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F218818\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F218831\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1049761\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F218811\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F218828\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F6133643\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F218833\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12971|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=rituximab-intravenous-drug-information\" class=\"drug drug_general\">Rituximab (intravenous): Drug information</a></li><li><a href=\"topic.htm?path=rituximab-intravenous-patient-drug-information\" class=\"drug drug_patient\">Rituximab (intravenous): Patient drug information</a></li></ul></div></div>","javascript":null}